Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1444

1.

Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.

Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D.

BJOG. 2013 Nov;120(12):1534-47. doi: 10.1111/1471-0528.12226. Epub 2013 Aug 7.

2.

When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery?

Read PJ, Mandalia S, Khan P, Harrisson U, Naftalin C, Gilleece Y, Anderson J, Hawkins DA, Taylor GP, de Ruiter A; London HIV Perinatal Research Group..

AIDS. 2012 Jun 1;26(9):1095-103. doi: 10.1097/QAD.0b013e3283536a6c.

PMID:
22441248
3.

CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.

McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.

Clin Infect Dis. 2005 Dec 1;41(11):1662-70. Epub 2005 Oct 19.

PMID:
16267741
4.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
5.
6.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
7.

Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort.

Kuyper LM, Wood E, Montaner JS, Yip B, O'connell JM, Hogg RS.

J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1470-6.

PMID:
15602125
8.

Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women.

Marazzi MC, Germano P, Liotta G, Guidotti G, Loureiro S, da Cruz Gomes A, Valls Blazquez MC, Narciso P, Perno CF, Mancinelli S, Palombi L.

HIV Med. 2006 Jul;7(5):338-44.

9.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
10.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003510. Review. Update in: Cochrane Database Syst Rev. 2011;(7):CD003510.

PMID:
17253490
11.

Influence of short-course antenatal antiretroviral therapy on viral load and mother-to-child transmission in subsequent pregnancies among HIV-infected women.

French CE, Tookey PA, Cortina-Borja M, de Ruiter A, Townsend CL, Thorne C.

Antivir Ther. 2013;18(2):183-92. doi: 10.3851/IMP2327. Epub 2012 Aug 22.

PMID:
23475123
12.

Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.

European Collaborative Study., Patel D, Cortina-Borja M, Thorne C, Newell ML.

Clin Infect Dis. 2007 Jun 15;44(12):1647-56. Epub 2007 May 2.

PMID:
17516411
13.

Does pregnancy affect the early response to cART?

Rachas A, Warszawski J, Le Chenadec J, Legeai C, Teglas JP, Goujard C, Rouzioux C, Mandelbrot L, Tubiana R, Meyer L.

AIDS. 2013 Jan 28;27(3):357-67. doi: 10.1097/QAD.0b013e32835ac8bc.

PMID:
23079802
14.

CD4, viral load response, and adherence among antiretroviral-naive breast-feeding women receiving triple antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV in Kisumu, Kenya.

Okonji JA, Zeh C, Weidle PJ, Williamson J, Akoth B, Masaba RO, Fowler MG, Thomas TK.

J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):249-57.

PMID:
22692094
15.

The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women.

McCabe CJ, Goldie SJ, Fisman DN.

PLoS One. 2010 Apr 13;5(4):e10154. doi: 10.1371/journal.pone.0010154.

16.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV..

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
17.

Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, Hayani K, Handelsman E, Smeriglio V, Hoff R, Blattner W; Women and Infants' Transmission Study Group..

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484-94.

PMID:
11981365
18.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Siegfried N, van der Merwe L, Brocklehurst P, Sint TT.

Cochrane Database Syst Rev. 2011 Jul 6;(7):CD003510. doi: 10.1002/14651858.CD003510.pub3. Review.

PMID:
21735394
19.

Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.

Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, Mahanontharit A, Ubolyam S, Cooper D, Phanuphak P, Ruxrungtham K.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):523-9.

PMID:
16044002
20.

Factors associated with viral load suppression in HIV-infected pregnant women in Rio de Janeiro, Brazil.

Joao EC, GouvĂȘa MI, Menezes JA, Sidi LC, Cruz ML, Berardo PT, Ceci L, Cardoso CA, Teixeira Mde L, Calvet GA, Matos HJ.

Int J STD AIDS. 2012 Jan;23(1):44-7. doi: 10.1258/ijsa.2011.010545.

PMID:
22362687

Supplemental Content

Support Center